Interstitial lung disease (ILD) causes significant morbidity and mortality in patients with systemic autoimmune rheumatic diseases. Patients at high risk of ILD should be screened using ...

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Patients with systemic autoimmune rheumatic disease who develop interstitial lung disease ...

Patients with inflammatory bowel disease (IBD) had a significantly higher risk for developing interstitial lung disease (ILD) compared with the general population and siblings who do not have the ...

New findings reveal that rheumatoid arthritis (RA) disease activity significantly affects the severity of interstitial lung disease (ILD), both radiologically and physiologically, in patients with RA ...

RILD in NHL patients presents as lung disease, organizing pneumonia, and nonspecific interstitial pneumonia, with 179 pathogenic microorganisms identified. The study systematically characterized RILD ...

The MarketWatch News Department was not involved in the creation of this content. CHICAGO, Aug. 28, 2025 /PRNewswire/ -- Eleven leading health advocacy organizations have joined forces to announce the ...

Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments ...